The therapeutic ratio is preserved for radiotherapy or cisplatin treatment in BRCA2-mutated prostate cancers

Prostate cancers in patients with a mutation in BRCA2 have earlier disease onset and an aggressive course, often necessitating the use of systemic therapy. However, these tumours are DNA repair-defective and could respond favourably to Parp inhibitors or DNA-damaging agents, depending on the therape...

Celý popis

Uloženo v:
Podrobná bibliografie
Hlavní autoři: Vesprini, Danny, Narod, Steven A, Trachtenberg, John, Crook, Juanita, Jalali, Farid, Preiner, John, Sridhar, Srikala, Bristow, Robert G
Médium: Artigo
Jazyk:Inglês
Vydáno: Canadian Medical Association 2011
Témata:
Case Report
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC3104437/
https://ncbi.nlm.nih.gov/pubmed/21470549
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.5489/cuaj.10080
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky